Associate Professor
Obstetrics & Gynecology | Faculty of Medicine
Senior Clinician Scientist | Child & Family Research Institute
Phone:
6048753054
Website:
Research Interests:

Project Name: Prediction in Pre-Eclampsia listed on the Implementation Research page.

Relevant NGDI Articles

2013

Early Administration of Low-Dose Aspirin for the Prevention of Severe and Mild Preeclampsia: A Systematic Review and Meta-Analysis.   Roberge S, Giguère Y, Villa P, Nicolaides K, Vainio M, Forest JC, von Dadelszen P, Vaiman D, Tapp S, Bujold E. Am J Perinatol. 2013 Mar 25. Review.

Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. Bickford CD, Magee LA, Mitton C, Kruse M, Synnes AR, Sawchuck D, Basso M, Senikas VM, von Dadelszen P; MAG-CP Working Group. BMC Health Serv Res. 2013 Dec 19;13:527.

Measuring maternal health: focus on maternal morbidity. Firoz T, Chou D, von Dadelszen P, Agrawal P, Vanderkruik R, Tunçalp O, Magee LA, van Den Broek N, Say L; Maternal Morbidity Working Group. Bull World Health Organ. 2013 Oct 1;91(10):794-6.

Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. Payne B, Hodgson S, Hutcheon JA, Joseph KS, Li J, Lee T, Magee LA, Qu Z, von Dadelszen P; PIERS Study Group. BJOG. 2013 Jan;120(1):113-8.

Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. Lalani S, Firoz T, Magee LA, Sawchuck D, Payne B, Gordon R, Vidler M, von Dadelszen P.  J Obstet Gynaecol Can. 2013 Mar;35(3):215-23.

Redefining preeclampsia using placenta-derived biomarkers. Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, Powers RW,  Charnock-Jones DS, Redman CW. Hypertension. 2013 May;61(5):932-42. Review.

2012

Challenges to transitioning from paper-based data collection to electronic data capture. Hoac T, Zahid A, Mason D, Sanchez J, Asztalos E, Hahnhaussen C, Kirton J, Ross S, von Dadelszen P and Magee LA. Clin Trials 2012 9(4):530.

Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: A systematic review and meta-analysis. Roberge S, Giguere Y, Villa P, Nicolaides K, Vainio M, Forest J-C, von Dadelzen P, Vaiman D, Tapp S and Bujold E.   Am J Perinatol 2012 29(7):551-556.

Improving maternal and perinatal outcomes in the hypertensive disorders of pregnancy: A vision of a community-focused approach. von Dadelszen P, Ansermino JM, Dumont G, Hofmeyr GJ, Magee LA, Mathai M, Sawchuck D, Teela K, Donnay F and Roberts JM.  Int J Gynecol Obstet 2012  119 (Suppl.1):S30-S34.

Magnesium sulphate for prevention and treatment of eclampsia in low and middle income countries: Systematic review of tested regimens. Gordon RM, Payne B, Firoz T, Magee L, Sawchuck D, Tu D, Vidler M and von Dadelszen P.  Pregnancy Hypertens 2012 2(3):328.

Measuring the burden of morbidity and mortality related to pre-eclampsia in developing countries-challenges and solutions. von Dadelszen P. Int J Gynecol Obstet 2012 119:S256.

Minipiers (pre-eclampsia integrated estimate of risk): Development of a clinical prediction model for use in low and middle income countries (LMIC). Payne B, Hutcheon JA, Qu Z, Haniff F, Bhutta Z, Biryabarema C, Duan T, Hall DR, Grobman WA, Groen H, Magee LA, Merialdi M, Mirembe F, Nakimuli A, Qureshi R, Sass N, Sikandar R, Steyn W, Widmer M, Zhou V and von Dadelszen P. Pregnancy Hypertens 2012 2(3):195-196.

Oral antihypertensive therapy for severe hypertension in pregnancy. Firoz T, Magee LA, Lalani S, Sawchuck D, Payne B, Vidler M, Gordon R and von Dadelszen P.  Pregnancy Hypertens 2012 2(3):288

Outcomes adjudication – The preparation process. Zahid A, Hoac T, Sanchez J, Hahnhaussen EAC, Kirton J, Ross S, vonDadelszen P and Magee LA. Clin Trials 2012 9(4):514.

Placental malaria infection as a risk factor for hypertensive disorders of pregnancy in malaria endemic regions: A systematic review and meta-analysis. Bodkin BL, Gordon R, Sawchuck D and Von Dadelszen P. Pregnancy Hypertens 2012 2(3):189.

Pharmacotherapy for pre-eclampsia in low and middle income countries: An analysis of essential medicines lists (EMLS). Lalani S, Firoz T, Magee LA, Lowe R, Sawchuck D, Payne B, Gordon R, Vidler M and von Dadelszen P. Pregnancy Hypertens 2012 2(3):193-194.

Serious unexpected events in an obstetric clinical trial – Definitional challenges. Magee LA, Menzies JM, Ross S, Sanchez J, Asztalos E, Kirton J, Hoac T, Zahid A, Hahnhaussen C and von Dadelszen P. Clin Trials 2012 9(4):516.

The PIERS experience: research or quality improvement? Firoz T, Magee LA, Payne BA, Menzies JM and von Dadelszen P. J Obstet Gynaecol Can  2012 34(4):379-381.

Timely prediction of maternal complications in pre-eclampsia analysis of the fullPIERS model. Akkermans J, Ganzevoort W, Payne B, Groen H, Mol BW and von Dadelszen P. Pregnancy Hypertens 2012 2(3):334-335.

2011

Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. Kozic JR, Benton S, Hutcheon JA, Payne BA, Magee LA, von Dadelszen P, et.al. Journal of obstetrics and gynaecology Canad a 2011, Vol33:10:995.

Assessment, surveillance and prognosis in pre-eclampsia. Best Practice & Research.Payne B, Magee LA, and von Dadelszen P. Clinical Obstetrics & Gynaecology 2011, Vol25:4:449-462.

Clinical risk prediction of pre-eclampsia. Magee LA and von Dadelszen P. British Medical Journal 2011, Vol342:7803:884.

Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. Millman AL, Payne B, Qu Z, Douglas MJ, Hutcheon JA, Lee T, Magee LA, Walley KR, and von Dadelszen P.  Journal of obstetrics and gynaecology Canada. 2011, Vol33:7:705.

PIERS proteinuria: relationship with adverse maternal and perinatal outcome. Payne B, Magee LA, Côté A-M, Hutcheon JA, Li J, Kyle PM, Menzies JM, Moore MP, Parker C, Pullar B, von Dadelszen P, and Walters BN.  Journal of obstetrics and gynaecology Canada.  2011, Vol33:6:588.

Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton-Pipkin F, Côté A-M, Douglas MJ, et.al. Lancet, 2011 Vol377:9761:219-227.

Pre-eclampsia in low and middle income countries. Best practice & research. Firoz T, Sanghvi H, Merialdi M, and von Dadelszen P. Clinical Obstetrics & Gynaecology 2011, Vol25:4:537-548.

Suboptimal vitamin D levels in pregnant women despite supplement use. Li W, Green TJ, Innis SM, Barr SI, Whiting SJ, Shand A, and von Dadelszen P. Canadian Journal of Public Health 2011, Vol102:4:308-312.

The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks’ gestation. Magee LA, von Dadelszen P, Allen VM, Ansermino JM, Audibert F, Barrett J, et.al. Journal of obstetrics and gynaecology Canada.  2011, Vol33:2:111.

Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. Yen T-W, Payne B, Qu Z, Hutcheon JA, Lee T, Magee LA, Walters BN, and von Dadelszen P. Journal of Obstetrics and Gynaecology Canada 2011, Vol33:8:803.